Superworth

Innoviva price to free cash flow INVA

Market value divided by free cash flow over the last twelve months, since 2016.

Today, Nov 2, 2026
8.0×
10-year median
6.3×
Against its 10-year history
76th
percentile: 0 is its lowest day, 100 its highest
10-year range
2.2× to 28.1×
Peer median
8.7×

Innoviva's price to free cash flow is 8.0× as of Nov 2, 2026.

That is above its ten-year median of 6.3×, higher than on 76% of days in the last ten years.

Over that time it ranged from 2.2× in Sep 2022 to 28.1× in Feb 2017.

The median for 10 large drugmakers of a similar size is 8.7×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far8.0×7.8×8.1×
20255.8×5.7×7.2×
20246.8×6.4×9.1×
20238.8×2.9×10.0×
20223.2×2.2×4.0×
20213.4×3.0×4.4×
20204.3×3.5×4.3×
2019n/m a value too high to mean anything
2018n/m a value too high to mean anything
201717.3×15.8×28.1×
201625.0×22.5×155×

Against its peers

Companies in Drug Manufacturers - General nearest Innoviva's size, closest first, today.

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Innoviva

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.